FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases

Alexion inks genomics pacts to continue R&D reboot August 11, 2017  – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]

Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement

Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases […]